|Bid||88.75 x 800|
|Ask||90.75 x 1000|
|Day's Range||88.87 - 89.98|
|52 Week Range||73.69 - 89.98|
|PE Ratio (TTM)||83.58|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||2.25 (2.57%)|
|1y Target Est||92.59|
INDIANAPOLIS , July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 ...
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
RIDGEFIELD, Conn. and INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Tradjenta® demonstrating similar cardiovascular safety compared with placebo. Boehringer Ingelheim and Eli Lilly and Company (LLY) announced the positive top-line results from the trial, which evaluated the impact of treatment with Tradjenta compared with placebo on cardiovascular safety on top of standard of care. The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.
INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- The U.S. label for Eli Lilly and Company's (LLY) once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease (CKD). The label now includes data from the AWARD-7 clinical trial, which showed that people treated with Trulicity 1.5 mg or 0.75 mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss, compared to those treated with traditional basal-bolus insulin.1 Trulicity is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist (RA) injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes.
Analysts expect Eli Lilly and Company (LLY) to report revenue of ~$6.1 billion during the second quarter, a 3.8% rise YoY (year-over-year) compared to $5.7 billion during the second quarter of 2017. Analysts expect its net income margin to expand to 22.5% during the second quarter compared to 20.2% during the second quarter of 2017, mainly due to a decrease in overall selling, general, and administrative expenses and a decrease in research and development expenses. Eli Lilly’s stock price has risen nearly 7.1% in the last 12 months and nearly 6.1% year-to-date.
A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.
Wall Street analysts expect an increase of ~3.8% in Eli Lilly and Company’s (LLY) second-quarter revenue to $6.1 billion following the strong performance of its new and existing products. Since Eli Lilly’s products are sold in over 120 countries worldwide, and its international sales contribute ~44% of its total revenue, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenue during the second quarter.
Eli Lilly is set to release its second-quarter earnings on July 24. Eli Lilly surpassed Wall Street analysts’ consensus estimates for EPS and revenue in the first quarter, reporting EPS of $1.34 on revenue of $5.7 billion. For the second quarter, analysts expect EPS of $1.30 for Eli Lilly on revenue of ~$6.0 billion.
The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients. Pfizer's shares were marginally up at $37.79 in premarket trade.
An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients.
Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Here is a look at the 10 biggest venture-backed IPOs and acquisitions from the first half of what has been a very active year for such exits.
INDIANAPOLIS, July 12, 2018 /PRNewswire/ -- Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured, and people in the deductible phase of their high-deductible insurance plans, Eli Lilly and Company (LLY) announced today. A customized suite of solutions for all Lilly insulins, including for Humalog® (insulin lispro), will be used by helpline operators to find answers that best fit the personal circumstances of patients.
We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication.